Pace Analytical® Acquires Emerson Resources, Inc. Adding Clinical Trial Material Production Capabilities
Acquisition allows Pace Life Sciences to serve pharmaceutical and biopharmaceutical companies from early-stage product development through phase II clinical trial material manufacturing.
Minneapolis, MN, August 25, 2020 – Pace Analytical® Services, LLC, the largest American-owned laboratory network providing environmental and life sciences analytical information and services, today announced that it has acquired Emerson Resources, Inc., a pharmaceutical contract development and manufacturing organization (CDMO) specializing in dosage form development and clinical trial material manufacturing.
“Adding Emerson Resources to our portfolio allows Pace Life Sciences to further support our pharmaceutical and biopharmaceutical clients from early-stage research and development through phase II clinical trial material manufacturing”, comments Eric Roman, CEO of Pace Analytical®. “For clients, this means seamless support through each critical milestone in bringing a new drug to market”.
Services provided by Emerson Resources are focused on solid oral dosage formulation development and the production of clinical trial materials in support of bringing pharmaceutical and biopharmaceutical products to market. “This acquisition expands the capabilities of Pace Life Sciences to include clinical trial material manufacturing, greatly rounding out our overall service offerings”, adds Greg Kupp, COO of the Pace Analytical® Life Sciences Division. “The production of clinical trial materials requires a robust quality system, deep technical expertise, and the agility to ensure materials are ready for the clinic on time. Emerson is exceptional in these areas and represents a strong addition to the Pace Analytical lab network.”
Emerson Resources principals Jay Signorino, COO and Chip Signorino, CFO, are exiting the family business and have been looking for a buyer with a good cultural fit. “Pace holds the same cultural values and aspirations as Emerson”, notes Jay Signorino. “We believe this will be an easy and beneficial transition for the Emerson team and our customers”.
Over the next six months, Emerson Resources will transition to operating under the Pace Analytical® brand. The Emerson Resources lab is in the Philadelphia, PA area and joins Pace Life Sciences lab locations near Boston, MA, St. Paul, MN, and San Germán, PR. Kupp will oversee the management and operations of all Pace Life Sciences lab locations.
About Emerson Resources
For more than 12 years, Emerson Resources, a premier pharmaceutical development company, has delivered value-added service, ingredients, and expertise to clients in the pharmaceutical and biotech industries. Emerson Resources is a leader in dosage form development, manufacturing cGMP clinical supplies, analytical method development, analytical method validation, release testing, and stability testing. Based in Norristown, Pennsylvania, the Company’s expansive facility features development and analytical laboratories, a cGMP clinical supplies manufacturing plant, and a specialty ingredients excipients manufacturing center. For more information, visit emersonresources.com.
About Pace Analytical®
Pace Analytical® Services, LLC makes the world a safer, healthier place. For decades, we have been the trusted source for quality environmental and life sciences lab testing and analysis and the resource for scientific lab staffing, regulatory, and equipment services. Our work is done in partnership with our clients by providing the science and the data they need to make critical decisions that benefit us all. Pace delivers science better to businesses, industries, consulting firms, government agencies, and more through the largest, American-owned and nationally certified laboratory network.